Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2021-08-13 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰关于持股5%以上股东减持股份计划公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from 百奥泰生物制药股份有限公司 regarding a planned reduction in shareholding by shareholders holding more than 5% of the company's shares. It details the shareholders involved, the number and percentage of shares to be reduced, the methods of reduction (centralized bidding and block trades), the timing, price conditions, and legal compliance. The content focuses on shareholding changes by major shareholders and their plans to sell shares, which aligns with notifications about significant share ownership changes or shareholding reductions. There is no indication that this is a full financial report, earnings release, or management discussion. The document is not a report publication announcement but a detailed disclosure of a shareholding reduction plan. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ).
2021-08-13 Chinese
百奥泰 2021年半年度业绩预告的自愿性披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement of the company's 2021 half-year performance forecast. It provides preliminary estimated financial results for the first half of 2021, including net profit and net loss figures, but explicitly states that these figures are unaudited and preliminary. It also mentions that the final accurate financial data will be disclosed in the formal 2021 half-year report. The document length is short (1188 characters) and it is clearly an announcement of expected financial results rather than a comprehensive interim report containing actual financial statements or detailed analysis. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement of performance forecast and not the full interim report itself.
2021-07-29 Chinese
百奥泰 关于与Biogen就BAT1806（托珠单抗）注射液签署授权许可与商业化协议收到首付款的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 百奥泰生物制药股份有限公司 regarding the signing of a licensing and commercialization agreement with Biogen International GMBH for the drug BAT1806 (tocilizumab injection). It details the receipt of an upfront payment and milestone payments related to the agreement. The document includes information about the board meeting approving the agreement, clinical trial results, payment details, and risk disclosures. The document is relatively short (1290 characters) and serves as an update on a capital/financing event rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the licensing agreement and payment progress. Therefore, it fits best under Capital/Financing Update (CAP).
2021-07-21 Chinese
百奥泰 自愿披露关于BAT6005注射液获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by 百奥泰生物制药股份有限公司 regarding the approval of a clinical trial for their drug BAT6005 injection by the National Medical Products Administration (国家药监局). It contains no financial data, no financial statements, and no detailed report content. It is an announcement of regulatory approval and risk warnings related to the clinical trial process. The document length is short (1633 characters) and it serves as a formal notification to investors about the clinical trial approval and associated risks. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit into other specific categories such as financial reports, management changes, or capital updates.
2021-07-20 Chinese
2021-028 百奥泰 自愿披露关于BAT6021注射液获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by 百奥泰生物制药股份有限公司 regarding the approval of a clinical trial for their drug BAT6021 injection by the National Medical Products Administration (国家药监局). It contains no financial data, no financial statements, no management discussion of financial results, nor any regulatory certifications or voting results. It is an announcement about a regulatory approval related to clinical trials, which is a regulatory update but not a financial report or management report. The document length is short (1680 characters), and it is clearly an announcement of an event rather than a report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-08 Chinese
百奥泰 自愿披露关于托珠单抗注射液（BAT1806）皮下制剂获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by 百奥泰生物制药股份有限公司 regarding the approval of a clinical trial for a drug (托珠单抗注射液 BAT1806) by the National Medical Products Administration (NMPA) of China. It includes details about the drug, the approval notice, and risk warnings related to the clinical trial and market competition. The document is relatively short (1370 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention the release or availability of a report. It is also not a regulatory filing in the sense of officer certifications or compliance documents. The content fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement about clinical trial approval and risk disclosure, which does not fit other more specific categories.
2021-05-06 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.